James Norris to Genetic Vectors
This is a "connection" page, showing publications James Norris has written about Genetic Vectors.
Connection Strength
0.579
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.244
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.068
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8.
Score: 0.055
-
Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003 Apr; 10(4):330-9.
Score: 0.049
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.045
-
Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol. 2002; 346:529-47.
Score: 0.045
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.043
-
Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res. 2008; 49(3):265-9.
Score: 0.017
-
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
Score: 0.013